Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

Полное описание

Библиографические подробности
Главные авторы:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
Формат:	Journal article
Язык:	English
Опубликовано:	Wiley 2017

Схожие документы

Telomere length is a critical determinant for survival in multiple myeloma
по: Hyatt, S, и др.
Опубликовано: (2017)

Maintenance of telomere length in AML
по: Peter M. Lansdorp
Опубликовано: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
по: Nadia El Menshawy, и др.
Опубликовано: (2020-07-01)

Inherited predisposition to MDS/AML
по: Ana Rio Machin, и др.
Опубликовано: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
по: Hamidollah Ghaffari, и др.
Опубликовано: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
по: Hamidollah Ghaffari, и др.
Опубликовано: (2009-06-01)

T cell memory revisited using single telomere length analysis
по: Laureline Roger, и др.
Опубликовано: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
по: Barbara De Moerloose
Опубликовано: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
по: Theilgaard-Mönch, K, и др.
Опубликовано: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
по: Jensen O, и др.
Опубликовано: (2022-02-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
по: Hoyle, C, и др.
Опубликовано: (1989)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
по: Olga K. Weinberg, и др.
Опубликовано: (2023-08-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
по: Goh, Chermaine Yu Zhen
Опубликовано: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
по: Joanna E. Zawacka
Опубликовано: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
по: V. Sheth, и др.
Опубликовано: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
по: A. G. Lema Fernandez, и др.
Опубликовано: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
по: A Amaro, и др.
Опубликовано: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
по: Petra Bašová, и др.
Опубликовано: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
по: Udit Bhaskar Bhatnagar, и др.
Опубликовано: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
по: Azra Raza, и др.
Опубликовано: (2020-01-01)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
по: Ana Rio-Machin, и др.
Опубликовано: (2020-02-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
по: Christoforos K. Vaxevanis, и др.
Опубликовано: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
по: YE Xiangjun, LU Xingguo
Опубликовано: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
по: V. Van Oorschot, и др.
Опубликовано: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
по: Hongjiao Li, и др.
Опубликовано: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
по: Lixian Chang, и др.
Опубликовано: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
по: Guancui Yang, и др.
Опубликовано: (2022-10-01)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
по: Barreyro, L, и др.
Опубликовано: (2012)

Telomere length in myelodysplastic syndromes.
по: Boultwood, J, и др.
Опубликовано: (1997)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
по: Anson Snow, и др.
Опубликовано: (2022-07-01)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
по: Tarik Möröy, и др.
Опубликовано: (2019-08-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
по: Zuzana Tothova, и др.
Опубликовано: (2021-02-01)

TELOMERE LENGTH AND ATHEROSCLEROSIS
по: O. M. Drapkina, и др.
Опубликовано: (2016-09-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
по: T. Ueda, и др.
Опубликовано: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
по: A. Shastri, и др.
Опубликовано: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
по: Sandra Huber, и др.
Опубликовано: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
по: Laura Barreyro, и др.
Опубликовано: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
по: Victoria V. Grunwald, и др.
Опубликовано: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
по: Amer M. Zeidan, и др.
Опубликовано: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
по: Tahsin Anwar, и др.
Опубликовано: (2023-12-01)